Ozemback
Compound file

Is ipamorelin legal? FDA status, the vote and what the evidence shows

Ipamorelin is not FDA approved and is not on the list of substances US pharmacies may compound. On 29 October 2024 an FDA advisory committee voted against listing it, 0 for, 12 against and 1 abstention, and the FDA keeps it in Category 2 for outsourcing facilities. It was not part of the July 2026 peptide review.

Status as of 20 November 2026
FDA approval
None. Ipamorelin is not a component of any FDA approved drug.
503A Bulks List
Not on it. No rule has added it.
503A interim categories
Not listed in any category of the FDA nominations list updated 14 May 2026.
503B (outsourcing facilities)
Category 2, significant safety risks, since 29 September 2023.
FDA staff recommendation
Against listing either form, in a briefing memo dated 19 August 2024.
Advisory committee, 29 October 2024
Voted against, 0 in favour, 12 against, 1 abstention, for the free base and the acetate alike.
PCAC July 2026 and HHS draft policy
Not part of either. Ipamorelin was not among the seven peptides reviewed in July 2026 or the six in the HHS draft of 30 October 2026.
Ozemback · Updated 20 November 2026 · Reviewed against primary sources
A bronze bell in a dark stone tower, a red rope hanging from it, lit by one shaft of light.
A peptide built to send one signal to the pituitary. Illustration, Ozemback.

The short version. Ipamorelin is not FDA approved and is not on the 503A Bulks List. FDA staff recommended against listing it, and on 29 October 2024 the advisory committee agreed, 0 to 12 with one abstention. Outsourcing facilities face it in Category 2. It was not part of the 2026 peptide review, and every human trial gave it into a vein.

NOIs ipamorelin FDA approved?No. The FDA briefing states neither ipamorelin free base nor ipamorelin acetate is a component of an FDA approved drug, and neither has a USP monograph.
NODid an FDA committee back it?No. On 29 October 2024 the Pharmacy Compounding Advisory Committee voted 0 in favour, 12 against and 1 abstention, per the FDA minutes.
NOIs it in the 2026 peptide policy?No. It was not reviewed in July 2026, and the Federal Register returns no 2025 or 2026 document naming it (checked 20 November 2026).
Three questions inside "is ipamorelin legal". Sources: FDA briefing document and minutes, PCAC 29 October 2024; FDA safety-risk page, current as of 22 April 2026; Federal Register API.
0-12-1committee vote on 29 October 2024: 0 for, 12 against, 1 abstention
114surgical patients in the only published efficacy trial, given ipamorelin or placebo into a vein
2deaths in the ipamorelin arm of that trial; the FDA says it is unclear whether they were drug-related
320patients in a second Helsinn trial, completed in 2014, with no results posted

What is ipamorelin?

Ipamorelin is a chain of five amino acids that binds the ghrelin receptor and makes the pituitary gland release growth hormone. Raun and colleagues at Novo Nordisk described it in 1998 in the European Journal of Endocrinology as the first selective growth hormone secretagogue: in pigs it released growth hormone without raising ACTH or cortisol, unlike the older GHRP-6 and GHRP-2. The FDA briefing prepared for the October 2024 Pharmacy Compounding Advisory Committee notes that the peptide contains unnatural amino acids, which make it harder to characterise, and that suppliers sell both a free base and an acetate salt. The two nominators, Wells Pharmacy Network and LDT Health Solutions, did not make clear which one they meant, so the FDA evaluated both.

The FDA briefing traces ipamorelin's use well beyond the clinic. Outsourcing facility reports show compounding with ipamorelin from 2017 to 2020, and internet searches found compounders preparing it as injections, nasal sprays and oral products. The FDA records that it is marketed for weight loss, anti-ageing, inflammatory conditions, sleep and bodybuilding, increasingly by medical spas and wellness clinics. A June 2026 review in Frontiers in Endocrinology by Dominikowski and colleagues groups ipamorelin with GHRP-2, GHRP-6 and hexarelin among the growth hormone secretagogues sold as research compounds for self-administration, and stresses that none has regulatory approval for physique or performance uses and that product composition, dose and stacking in unregulated supply chains are uncertain.

Five smooth dark stones in a short line on wet black slate, the middle stone deep red.
Five amino acids, two of them not found in nature. Illustration, Ozemback.

In plain EnglishIpamorelin is a small lab-made peptide that tells the pituitary to release growth hormone. A drug company tested it in hospitals for bowel recovery after surgery. Today it is sold online for muscle, fat loss and ageing. In the US it is not an approved drug.

Ipamorelin's legal position rests on four dated facts, and all four point the same way. First, the FDA briefing states that neither form is a component of an FDA approved drug, and neither has a USP or National Formulary monograph. Second, ipamorelin is not on the 503A Bulks List, and it does not appear in any interim category of the FDA nominations list updated 14 May 2026; the Federal Register API returned no 2025 or 2026 document naming ipamorelin when we checked on 20 November 2026. Third, the FDA safety-risk page, current as of 22 April 2026, keeps ipamorelin acetate in 503B Category 2, the group that may present significant safety risks, since 29 September 2023. Fourth, the committee voted against it.

QuestionWhat the record saysSource
FDA approved product?None. Not a component of any approved drug FDA briefing, PCAC October 2024
On the 503A Bulks List?No No proposed or final rule
503B statusCategory 2, significant safety risks, since 29 Sep 2023 FDA safety-risk page, 22 Apr 2026
FDA staff viewAgainst listing either form FDA briefing memo, 19 Aug 2024
Advisory committeeAgainst: 0 for, 12 against, 1 abstention FDA minutes, 29 Oct 2024
July 2026 review and HHS draft policyNot included in either Federal Register API, 20 Nov 2026

The 2024 vote is the fact most pages ranking for ipamorelin leave out. On 29 October 2024 the committee first agreed, 12 to 1, to vote on the free base and the acetate as a group, then voted 0 in favour, 12 against and 1 abstention on each. According to the FDA minutes, members who voted no cited a lack of information supporting safety and efficacy for growth hormone deficiency and post-operative ileus, and one member said that how often a drug is prescribed does not show it is safe and effective. The abstaining member pointed to confusion between data on the two forms. A committee vote is advice, not a rule, but the advice was unanimous among those who voted.

Ipamorelin on the record

  1. 1998Raun and colleagues at Novo Nordisk describe ipamorelin as the first selective growth hormone secretagogue
  2. 1999Gobburu and colleagues publish a dose-escalation study in 48 healthy men, intravenous
  3. 2008-2009First Helsinn phase 2 trial in post-operative ileus, 117 patients enrolled (NCT00672074)
  4. 2011-2014Second Helsinn phase 2 trial, 320 patients enrolled; no results posted (NCT01280344)
  5. 2014Beck and colleagues: no significant difference from placebo
  6. 29 Sep 2023FDA places ipamorelin acetate in 503B Category 2, significant safety risks
  7. 19 Aug 2024FDA staff memo against listing on the 503A Bulks List
  8. 29 Oct 2024Advisory committee votes against, 0 to 12 with one abstention
Sources: PubMed; ClinicalTrials.gov; FDA safety-risk page; FDA briefing document and minutes, PCAC 29 October 2024.
A dark hearing room with a long curved table and empty chairs, one lamp with a red shade lit.
Twelve no votes, one abstention, no yes. Illustration, Ozemback.

In plain EnglishThe FDA asked its outside experts in 2024 whether pharmacies should be allowed to make ipamorelin. Twelve said no and one did not vote. Nothing since has changed that, and ipamorelin was not part of the 2026 peptide decisions that made headlines.

Ipamorelin is sold as an injection under the skin. The FDA found no safety data for that route, and its committee voted 0 to 12 against letting pharmacies compound it.

The 2026 news on peptides does not cover ipamorelin. The committee that met on 23 and 24 July 2026 reviewed seven peptides, BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax and emideltide, and the HHS draft enforcement policy published on 30 October 2026, FR Doc. 2026-22192, names six. Ipamorelin is not in either group, because its own review had already ended in October 2024. The Ozemback peptide legal status tracker shows the legal position of 28 compounds with the date of each fact, and the approved, recommended or neither quiz tests how well the headlines held up. For the July meeting, see our analysis of the vote.

Does ipamorelin work?

The FDA's conclusion: the trials did not show a significant benefit for post-operative ileus, there are no effectiveness data for growth hormone deficiency, and none for the injection under the skin that was nominated.

Two hourglasses on a dark table by candlelight, one with red sand, one with pale sand.
Seven hours faster to a first meal, and not statistically significant. Illustration, Ozemback.

The only published efficacy trial is Beck and colleagues, 2014, in the International Journal of Colorectal Disease. It was a phase 2, double-blind, placebo-controlled study run with Helsinn (NCT00672074): 117 adults having small or large bowel resection were enrolled and 114 were analysed, 56 on intravenous ipamorelin twice daily and 58 on placebo, for up to seven days. The median time to a first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a gap of 7.3 hours that was not statistically significant (p = 0.15), and secondary endpoints showed no difference either. A second Helsinn phase 2 trial, NCT01280344, enrolled 320 patients and was completed in May 2014, but ClinicalTrials.gov shows no posted results as of 20 November 2026.

The growth hormone deficiency claim rests on even less. The nominators cited Gobburu and colleagues, 1999, a randomised, placebo-controlled dose-escalation study in 48 healthy men that measured how ipamorelin moves through the body and how much growth hormone it releases. That study found a half-life of about two hours and a single pulse of growth hormone peaking at around 40 minutes. The FDA notes it did not diagnose or treat anyone with growth hormone deficiency, and the agency found no other publication that did. FDA approved growth hormone products exist for that condition, which the briefing lists.

Adverse events more frequent on ipamorelin than placebo, Beck 2014 (% of patients)

Hyperglycaemia at discharge, ipamorelin
14.3%
Hyperglycaemia at discharge, placebo
8.6%
Low potassium, ipamorelin
12.5%
Low potassium, placebo
3.4%
Insomnia, ipamorelin
10.7%
Insomnia, placebo
5.2%
FDA briefing document on ipamorelin-related bulk drug substances, PCAC 29 October 2024 (memo dated 19 August 2024), summarising Beck et al. 2014: 56 patients on intravenous ipamorelin, 58 on placebo, after bowel resection.

Committee vote on ipamorelin, 29 October 2024

In favour
0
Against
12
Abstained
1
FDA, minutes of the Pharmacy Compounding Advisory Committee, 29 October 2024. The same result for ipamorelin free base and ipamorelin acetate.

In plain EnglishA drug company tested ipamorelin on patients recovering from bowel surgery. They ate a few hours sooner on average, but not by enough to rule out chance, and a bigger trial never published its results. Nobody has shown it treats growth hormone deficiency.

What has been reported on safety

The FDA's safety concerns start with the trial itself. In the Beck study, as summarised in the FDA briefing, low potassium (12.5 percent versus 3.4), insomnia (10.7 versus 5.2) and high blood sugar at discharge (14.3 versus 8.6) were more frequent on ipamorelin than on placebo. Two patients on ipamorelin, both operated on for colon cancer, died after anastomotic leaks, with sepsis among the causes of death; the FDA states it is unclear whether the deaths were related to ipamorelin, but says their occurrence, alongside the potassium and glucose findings, raises safety concerns. The FDA's FAERS search through 30 September 2023 found two non-serious reports. The agency also flagged immunogenicity and aggregation risk for an injected peptide with unnatural amino acids.

What is the ipamorelin dosage?

There is no FDA approved dose of ipamorelin, because there is no FDA approved product.

Every ipamorelin dose figure online comes from somewhere other than a US label. The Helsinn trials and the 1999 volunteer study gave the peptide into a vein, dosed by body weight, in hospital or research settings, which says nothing about the subcutaneous injections, nasal sprays and oral products sold today. The FDA briefing says it has not identified safety information for ipamorelin by other injectable routes, so the agency lacks the data to know whether it would cause harm given that way. The briefing also warns that it has no data to rule out the risks seen with approved products that raise growth hormone. We report this because it is the record, and we do not publish a recommended dose, cycle, stack or protocol for ipamorelin or any other compound.

What is still unknown about ipamorelin?

A figure seen from behind in a dark corridor before a closed heavy door, a line of red light beneath it.
What is still unknown. Illustration, Ozemback.

How should you read other pages about ipamorelin?

Check whether the page mentions the October 2024 vote at all; many ipamorelin pages describe the 2026 peptide wave as if it covered every growth hormone peptide, and this one was voted down two years earlier. Check whether the "selective" and "few side effects" claims cite the 1998 pig study or a human trial, and whether that trial gave ipamorelin into a vein, as all of them did, or the way the page is selling it. Check who pays the author: nearly every site ranking for ipamorelin benefits or dosage sells it, sells a consultation or links to a seller. This page carries a date at the top, 20 November 2026, so you can tell when it stops being current. Related files: Sermorelin and Tesamorelin, the growth hormone releasing peptides with an FDA approval history.

The questions people actually type

Is ipamorelin legal in the US?

Ipamorelin is not an FDA approved drug and is not on the 503A Bulks List of substances pharmacies may compound. An FDA advisory committee voted against listing it on 29 October 2024, 0 for, 12 against and 1 abstention, and the FDA lists ipamorelin acetate in Category 2 for outsourcing facilities. Whether a specific seller is acting lawfully is a question for a lawyer.

Is ipamorelin FDA approved?

No. The FDA briefing for the October 2024 committee states that neither ipamorelin free base nor ipamorelin acetate is a component of an FDA approved drug, and neither has a United States Pharmacopeia monograph. Its only efficacy trials, two Helsinn phase 2 studies in bowel surgery, gave it into a vein.

Is ipamorelin part of the 2026 peptide changes?

No. The FDA committee of 23 and 24 July 2026 reviewed seven peptides, and the HHS draft policy of 30 October 2026 covers six. Ipamorelin is in neither. Its committee vote happened in October 2024, and it went against. The peptide legal status tracker shows where each compound stands.

Does ipamorelin work?

The record does not show a clinical benefit. In the only published efficacy trial, 114 patients after bowel surgery, the median time to a first tolerated meal was 25.3 hours on ipamorelin and 32.6 on placebo, a difference that was not statistically significant. The FDA found no effectiveness data for growth hormone deficiency.

What is the ipamorelin dosage?

There is no FDA approved dose, because there is no FDA approved product. The trials gave ipamorelin into a vein, dosed by body weight, in hospital, which tells you nothing about the injections sold online. We do not publish a dose, cycle or protocol for this or any compound.

What are the side effects of ipamorelin?

In the 2014 surgical trial, low potassium, insomnia and high blood sugar at discharge were more frequent on ipamorelin than on placebo, and two patients on ipamorelin died after complications; the FDA says it is unclear whether the deaths were related to the drug. The FDA found no safety data for injection under the skin.

Is ipamorelin the same as CJC-1295?

No. Ipamorelin acts on the ghrelin receptor, while CJC-1295 is a growth hormone releasing hormone analogue, and the two are often sold together. Neither is FDA approved, and the FDA safety-risk page lists concerns about each. The tracker carries both.

Sources

  1. FDA. Briefing document: ipamorelin-related bulk drug substances (ipamorelin free base and ipamorelin acetate). Pharmacy Compounding Advisory Committee, 29 October 2024 (evaluation dated 19 August 2024). www.fda.gov
  2. FDA. Minutes of the Pharmacy Compounding Advisory Committee meeting, 29 October 2024. www.fda.gov
  3. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. www.fda.gov
  4. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. pubmed.ncbi.nlm.nih.gov
  5. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. pubmed.ncbi.nlm.nih.gov
  6. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. pubmed.ncbi.nlm.nih.gov
  7. ClinicalTrials.gov. NCT01280344, Safety and efficacy of ipamorelin compared to placebo for the recovery of gastrointestinal function (Helsinn). Checked 20 November 2026. clinicaltrials.gov
Cite this pageOzemback. "Ipamorelin: status, evidence and dose." Compound file, updated 20 November 2026. https://ozemback.com/compounds/ipamorelin/
Where to go from here

Get a baseline you can actually measure

Whatever you decide, your own numbers are the one part of this that is not contested. A baseline panel costs less than a month of most things sold in this category and it is yours to keep.

Ozemback is not a provider and takes no part in any clinical decision. The link above is an affiliate link: if you buy a panel through it we receive a commission at no additional cost to you. We are paid for the referral, never for the result, and it does not change what we publish.

Ozemback is an independent publication. This page reports what regulators, published trials and other sites state about this compound, with a source beside each claim. It is editorial analysis, not medical advice. It does not recommend a dose, a protocol or a course of action, and nothing here should be used to start, stop or change a treatment. Talk to a licensed clinician.
Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer
Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer